Campaign
Epitheal
Pharma
Epitheal Limited has developed a patent-pending compound for treating skin damage and disease, which will be available over the counter and without a prescription.
€
400,000 Funding goal
€
393,412 Invested
79Investors
Company Summary :
Epitheal’s patent-pending compound is a natural product, requiring no prescription and delivers faster superior skin-healing results described as ‘gold dust’ in the industry.
Key highlights:
- Initial commercial focus is on the equine healthcare market is driven by Ireland’s strong international reputation and an attractive growth rate of 6.8% CAGR to 2030, reaching a value of $2.3 billion globally.
- Company already has established laboratory facilities and premises.
- Extensive R&D conducted; incl. Safety & efficacy clinical trials completed, field trials completed.
- Irish Government & EU funding approved (€250k) via Udaras Na Gaeltachta.
- Presently seeking medicines approval to enter the veterinary markets Q4, 2025 and the human medicines market 2027.